Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Sudeep Pharma Ltd (SUDEEPPHRM) is currently trading at 886.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets. Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter. Management is executing a clear capacity roadmap: Nandesari greenfield (51,200 MT, ~Rs.150 crore) commissioning by Q4 FY26 and Dahej battery materials Phase‑1 (25,000 MT, ~Rs.300 crore) targeted for early CY27, indicating a strategic pivot into high‑growth battery materials while expanding core pharma and specialty capacities. Sudeep’s battery strategy positions it as an early large non‑Chinese LFP supplier: the company reports 34 battery value‑chain customers, 26 approvals, multiple MoUs and commercial orders from upgraded capacity, leveraging a proprietary ‘green chemistry’ claim and port proximity to serve global OEMs and CAM producers. Product and regulatory moats are meaningful: 6 proprietary technologies, 420 R&D projects, multiple global certifications (FDA, EDQM, EXCiPACT) and long customer relationships (average >7 years for top customers) underpin pricing power, repeat business (84% repeat revenue) and faster entry into regulated markets such as Europe and North America.
Over the past 52 weeks, Sudeep Pharma Ltd has traded between a low of ₹524.95 and a high of ₹893.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sudeep Pharma Ltd has a market capitalization of approximately 9,676.31. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sudeep Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.96 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9,676.31 Cr, Sudeep Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sudeep Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 55.96. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
6
Neutral
6
Bullish
2
Bearish
6
Neutral
10
Bullish
30
Bearish
0
Neutral
4
Bullish
28
Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets.
Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter.
Management is executing a clear capacity roadmap: Nandesari greenfield (51,200 MT, ~Rs.150 crore) commissioning by Q4 FY26 and Dahej battery materials Phase‑1 (25,000 MT, ~Rs.300 crore) targeted for early CY27, indicating a strategic pivot into high‑growth battery materials while expanding core pharma and specialty capacities.
Sudeep’s battery strategy positions it as an early large non‑Chinese LFP supplier: the company reports 34 battery value‑chain customers, 26 approvals, multiple MoUs and commercial orders from upgraded capacity, leveraging a proprietary ‘green chemistry’ claim and port proximity to serve global OEMs and CAM producers.
Product and regulatory moats are meaningful: 6 proprietary technologies, 420 R&D projects, multiple global certifications (FDA, EDQM, EXCiPACT) and long customer relationships (average >7 years for top customers) underpin pricing power, repeat business (84% repeat revenue) and faster entry into regulated markets such as Europe and North America.
Pharmaceuticals & Biotechnology
Pharmaceuticals
10,012 Cr
Low Risk
57.9
37.2
4.4
11.0
893.40
524.95
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6780.50 | 11,257 Cr | 34.43 | 21.46 | 6.12 | 62.32 | 84.14 | 38.86 | ||
576.55 | 10,906 Cr | 44.01 | 5.05 | 0.19 | 18.22 | 24.16 | 15.10 | ||
4671.45 | 10,773 Cr | 41.77 | 28.05 | 1.60 | 62.53 | 75.60 | 47.15 | ||
676.00 | 10,638 Cr | 41.69 | 3.21 | 0.43 | 7.70 | 10.95 | 4.71 | ||
868.00 | 9,676 Cr | 55.96 | 10.95 | 0.00 | 19.57 | 22.16 | 14.83 | ||
1045.20 | 9,623 Cr | 17.30 | 3.10 | 0.48 | 17.90 | 17.30 | 8.29 | ||
3370.70 | 8,112 Cr | 19.63 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
| Median: 7 Co. | — | 1045.20 | 10,638 Cr | 41.69 | 9.43 | 0.48 | 19.57 | 24.16 | 15.10 |
Earnings Call/Transcript
Sudeep Pharma will hold its Q1 FY27 earnings call on 2026-08-05 at 11:00 IST (hosted by Nuvama) to discuss operational and financial performance for quarter ended 30 June 2026. Registration link on company website.
Earnings Call/Transcript
Sudeep Pharma to hold Q1 FY27 earnings call on Wednesday, 5 Aug 2026 at 11:00 AM IST hosted by Nuvama Wealth Management; management to participate. Registration link on company website.
Board Meeting
Sudeep Pharma Ltd: Board meeting on 2026-08-04 to consider and approve unaudited standalone & consolidated financial results for quarter ended 30 June 2026. Trading window closed from 2026-07-01 to 2026-08-06.
Board Meeting
Sudeep Pharma to hold Board meeting on 2026-08-04 to consider and approve unaudited standalone & consolidated financial results for quarter ended 30 Jun 2026. Trading window closed 2026-07-01 to 2026-08-06.
